Talaris Therapeutics Stock Forecast, Price & News

-0.37 (-2.61 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume21,967 shs
Average Volume37,242 shs
Market Capitalization$570.49 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TALS News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Talaris Therapeutics

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.03 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Talaris Therapeutics (NASDAQ:TALS) Frequently Asked Questions

Is Talaris Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Talaris Therapeutics stock.
View analyst ratings for Talaris Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Talaris Therapeutics?

Wall Street analysts have given Talaris Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Talaris Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Talaris Therapeutics' next earnings date?

Talaris Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 13th 2021.
View our earnings forecast for Talaris Therapeutics

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Sunday, June, 13th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $1.04.
View Talaris Therapeutics' earnings history

What price target have analysts set for TALS?

4 equities research analysts have issued 12 month price objectives for Talaris Therapeutics' stock. Their forecasts range from $21.00 to $35.00. On average, they expect Talaris Therapeutics' stock price to reach $29.25 in the next year. This suggests a possible upside of 111.8% from the stock's current price.
View analysts' price targets for Talaris Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Talaris Therapeutics' key executives?

Talaris Therapeutics' management team includes the following people:
  • Mr. Scott Requadt L.L.B., M.B.A., J.D., MBA, Pres, CEO, Sec. & Director (Age 53)
  • Dr. Suzanne T. Ildstad M.D., Founder, Chief Scientific Officer & Director (Age 68)
  • Ms. Mary Kay Fenton, Chief Financial Officer (Age 57)
  • Mr. Michael Zdanowski, Chief Technology Officer (Age 54)
  • Ms. Suzanne Tollerud, VP of Corp. Devel. & Treasurer
  • Mr. Roderick D. Purdy, VP of HR (Age 64)
  • Ms. Nancy Krieger M.D., Chief Medical Officer (Age 54)
  • Mr. Eric Gornstein, Head of New Product Planning
  • Ms. Farah Natoli, Head of Portfolio & Program Management

Who are some of Talaris Therapeutics' key competitors?

When did Talaris Therapeutics IPO?

(TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

What is Talaris Therapeutics' stock symbol?

Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS."

When did the company's quiet period expire?

Talaris Therapeutics' quiet period expired on Wednesday, June 16th. Talaris Therapeutics had issued 8,825,000 shares in its public offering on May 7th. The total size of the offering was $150,025,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Talaris Therapeutics?

Shares of TALS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Talaris Therapeutics' stock price today?

One share of TALS stock can currently be purchased for approximately $13.81.

How much money does Talaris Therapeutics make?

Talaris Therapeutics has a market capitalization of $570.49 million.

How many employees does Talaris Therapeutics have?

Talaris Therapeutics employs 82 workers across the globe.

What is Talaris Therapeutics' official website?

The official website for Talaris Therapeutics is

How can I contact Talaris Therapeutics?

The company can be reached via phone at 502-398-9250.

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.